First, compounds were selected as targeted therapies that had a significant negative correlation (p < 0.05, Pearson’s correlation test) between drug response measurements (IC50, ln(IC50), EC50, ln(EC50)) and gene expression of one of four ICIs (CD27, PD1, CTLA4, or PDL1) in human NSCLC epithelial cell lines (n = 135). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.